Lilly holds industry-leading growth potential as the company is launching several new blockbusters and patent losses are fading. We are holding steady to our fair value estimate for EliLilly ...
EliLillyand Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) approved EBGLYSS™ (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and ...
Some results have been hidden because they may be inaccessible to you